TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01279291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KHK2866
Description: Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KHK2866
Description: Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Prevnar
Description: 3-dose intramuscular injection at 2, 4 and 6 months of age, and 1 booster dose by intramuscular injection at 12 to 15 months of age.
Study: NCT01279291

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: KHK2866
Description: Potentially therapeutic monoclonal antibody for the treatment of advanced cancer and ovarian cancer.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine and Carboplatin
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-sensitive ovarian cancer. Gemcitabine dose 1000 mg/m2, Carboplatin dose AUC=4
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age.
Study: NCT01279291

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. Paclitaxel will be administered weekly at a dose of 80 mg/m2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegylated liposomal doxorubicin
Description: Combination chemotherapy with KHK2866 to treat advanced platinum-resistant ovarian cancer. PLD will be administered weekly at a dose of 40 mg/m2.
Study: NCT00740454

Intervention type: OTHER
Intervention: Lower limb veins compression ultrasonography
Description: Distal and proximal lower limb veins compression ultrasonography
Study: NCT00651014

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ezetimibe
Description: oral tablet; ezetimibe 10 mg once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablet; ezetimibe placebo once daily for 6 weeks (added to ongoing simvastatin 10 or 20 mg once daily)
Study: NCT04022525

Intervention type: DRUG
Intervention: Leflunomide 20Mg Tab
Description: blood samples of rheumatoid patients will be collected for SNPs detection and drug assay
Study: NCT01290146

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diuretics
Description: Patients randomized to diuretics receive a 24-hour diuretic infusion with a maximum cumulative dose up to 200 mg furosemide/24 h

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levosimendan
Description: Patients randomized to Levosimendan receive a 24-hour levosimendan infusion with NO prior bolus injection.~Starting doses will be based on baseline SBP levels~* SBP ≥ 85-99mmHg: 0.05 mcg/kg/min~* SBP ≥100 mmHg: 0.1 mcg/kg/min
Study: NCT00708747

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albumin (5% serum-protein solution containing immunoglobulins)
Description: 5% albumin was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Biseko
Description: Standardised 5% serum-protein solution (Biseko, Biotest, Dreieich, Germany) was given intravenously at a volume of 1,000 ml on the first day and 500 ml/day during the following four days.
Study: NCT02020798

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Study: NCT00289783

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: M-M-R II
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varivax
Description: 1 booster dose by subcutaneous injection at 12 to 15 months of age
Study: NCT00716534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 12.5 mg ABT-869

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo for ABT-869
Description: Placebo Comparator (12.5 mg or 7.5 mg)
Study: NCT03345355

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Coronal oblique T1, Coronal oblique and axial STIR, Coronal oblique T1 Dixon, Coronal oblique and Axial T2 Dixon and T1 Dixon post Gadolinium
Study: NCT00716534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABT-869
Description: 7.5 mg ABT-869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6 mg/mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin (AUC 6 mg/mL/min)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Carboplatin
Description: Carboplatin (AUC 6 mg/mL/min)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (200 mg/m2)
Study: NCT03256643

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Exercise intervention will consist of 8 exercise classes and exercises at home. A booklet will be given to each person that has a description and photograph of each exercise that designed to work on core strength and balance.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed Exercise
Description: People will be tested up to 40 weeks after beginning the intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise and enrichment
Description: Exercise and enrichment will consist of the same exercise program described for the exercise intervention. The enrichment protocol consisting of cultural educational program will take place during the exercises and breaks for this group.
Study: NCT05152030

Intervention type: DIAGNOSTIC_TEST
Intervention: 'TIB' Olfactory Test
Description: A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.

Intervention type: DIAGNOSTIC_TEST
Intervention: 'TIB' Olfactory Test
Description: A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.

Intervention type: DIAGNOSTIC_TEST
Intervention: 'TIB' Olfactory Test
Description: A new smell identification test, 'TIB' Olfactory Test Device (Top International Biotech, Taipei) has been developed in Taiwan. It consists of 16 tests with an odorant embedded in fragrant microcapsules positioned on a strip. The examinee scratches the strip to release the odorant. The released odorant is sniffed and the examinee identifies the odorant by choosing a name from a set of 4 odor descriptors. This process is then repeated with the next odorant on the strip.
Study: NCT04312477

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modified Gegen Qinlian Decoction
Description: Modified Gegen Qinlian Decoction contains Pueraria lobata 24g, Scutellaria baicalensis 9g, Coptis chinensis 9g, artillery ginger 9g, talc 9g, roasted licorice 6g, and granules are prepared according to 10:1 production process.
Study: NCT00302744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin (drug)
Description: Capsule (.2 mg/kg).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Niacin
Description: Active Placebo

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: MRI
Description: MRI required for study inclusion for purpose of ruling out metasteses to brain

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI
Description: MRI required for study inclusion for purpose of ruling out metasteses to brain
Study: NCT02229708

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Lifestyle Group
Study: NCT03469622

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EndoRings
Description: EndoRings-assisted colonoscopy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard colonoscopy
Description: Standard colonoscopy without any additional devices
Study: NCT01163305

Intervention type: DRUG
Intervention: Chemotherapy
Description: The majority of patients offered either oxaliplatin or irinotecan-based chemotherapy
Study: NCT02648009

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized (13) Pyruvate Injection
Description: MRI with Hyperpolarized Pyruvate (13) Injection

Intervention type: DRUG
Group type: OTHER
Intervention: Hyperpolarized (13) Pyruvate Injection
Description: MRI with Hyperpolarized Pyruvate (13) Injection

Intervention type: DRUG
Group type: OTHER
Intervention: Gadolinium
Description: MRI with Gadolinium
Study: NCT04212078

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin Ophthalmic
Description: 0.1ml which has 0.5 mg levofloxacin will be injected via intracameral into the anterior chamber through the side port wound using a tuberculin syringe in a 27 gauge cannula.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefuroxime
Description: The vial contains 750 mg of cefuroxime powder is diluted with 7.5 ml of Balanced Salt Solution (BSS). 1 ml of the solution will be withdrawn and added with 9 ml of BSS. Then, 0.1 ml of solution which is equivalent to 1 mg of cefuroxime will be aspirated and kept a side. The dissolution of the antibiotic is confirmed by naked eye. Then the antibiotic of 0.1 ml will be given as intracameral to patient using a tuberculin syringe in a 27 gauge cannula at side port wound at the end of surgery.
Study: NCT00792740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ITF2357
Description: ITF2357 was administered as hard gelatin capsules for oral administration at the dose strength of 50 mg. Capsules were administered as follow: one capsule in the morning and one in the evening.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo was supplied as matching capsules for oral administration with the same outer appearance of the study drug and with the same dosing scheme (one capsule in the morning and one in the evening)
Study: NCT00556439

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Abatacept
Description: Participants will receive a fixed dose of abatacept, approximating 10mg per kilogram of body weight. The following dosing rules will be followed:~* Participants weighing less than 60kg will receive 500mg of abatacept.~* Participants weighing 60 to 100kg will receive 750mg of abatacept.~* Participants weighing more than 100kg will receive 1000mg of abatacept.~Abatacept will be administered in a 30-minute intravenous infusion on Days 1, 15, 29 (Month 1) and at Month 2. In the absence of toxicity or relapse, participants will remain on abatacept at the same dosage until randomization at Month 3. After randomization, only Group A (giant cell arteritis) and Group C (Takayasu arteritis) participants will continue on abatacept.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo abatacept infusions will be given monthly after random assignment at Month 3.
Study: NCT04328896

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CGM-Tele-monitoring
Description: Baseline Visit-Visit 0~1. Obtain informed consent~2. Administer questionnaires~3. Measure A1C~4. Start study Dexcom CGM device (those already on CGM will change to the study device).~5. The patient will be signed into Tidepool using a research code name and email.~Visit 1-2 weeks~1. 14 days worth of data will be downloaded from the patient's CGM device.~2. Systems will be checked to be sure they are functioning~3. Remote monitoring program will be activated.~4. Telemedicine procedure will be discussed with patient; emergency contact numbers will be obtained in case patient cannot be reached~Visit 2-14 weeks~1. Administer questionnaires~2. Measure A1C.~3. Collect CGM data and compare to baseline~Testing and Assessments:~* Continuous glucose monitoring~* Tidepool cloud upload~* HbA1c~* T1D REDEEM diabetes distress questionnaire~* Hypoglycemia Fear Survey~* Assessment of Severe Hypoglycemia and Diabetic Ketoacidosis
Study: NCT00804050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: infusion A: rEPO
Description: rEPO 40.000 unit/week for 4 mounths, then patients who have obtained an erythroid response, will continue for another 4 months with therapy rEPO. Patients who have not obtained an erythroid response, will increase the dose rEPO to 80,000 units per week for an additional 4 months.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B Infusion rEPO combined with vitamins pills
Description: rEPO 40.000 unit/week plus acid 13 cis-retinoic (20 mg/die) plus Dihydroxyvitamin D3 (1 μg os/die), for 4 mounths. Patients who have obtained an erythroid response will continue for another 4 months with the same therapy. Patients who have not obtained an erythroid will increase the dose of rEPO to 80,000 units per week for additional 4 months.Patients also will continue with the same doses of acid 13-cis-retinoic acid and Dihydroxyvitamin D3
Study: NCT00562432

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Plexisyl-AF
Description: Plexisyl-AF implants

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Plexisyl-AF
Description: Plexisyl-AF implants

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: No Treatment
Description: CABG without the experimental treatment
Study: NCT00701103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion
Study: NCT01674153

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra-dialytic exercise
Description: Perform intra-dialytic exercise of three bouts in 4 hours dialysis session. Each patient will perform exercise on Monark 881E rehab trainer (widely used in routine dialysis settings). The exercise intensity will be prescribed based on achievement of 50% of maximum heart rate for each recruited subject.
Study: NCT00701103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion
Study: NCT03902132

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core Stability exercises group
Description: Core Stability Exercises were given in addition to the traditional physical therapy treatment as given to the control group. It included moist heat pack (10mins), Transcutaneous Electrical Nerve Stimulation (10 min), and strengthening regimen (2 sets with 15 isometric repetitions each).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional low back physical therapy group
Description: The control group was given traditional low backache physical therapy management such as moist heat pack, TENS, and strengthening regimen (2 sets with 15 isometric repetitions each)
Study: NCT03382730

Intervention type: OTHER
Group type: OTHER
Intervention: Chlorhexidine Mouth Rinse
Description: Oral chlorhexidine gluconate oral rinse

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Mouth Rinse De-Adoption
Description: Multifaceted education and audit/feedback.
Study: NCT02778659

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zolpidem
Description: The hypnotic will be administrated orally at 22:00 in the evening before a sleep recording and an early wake-up at 01:00 for cognitive and motor assessment.
Study: NCT00701103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dalotuzumab
Description: IV infusion
Study: NCT03402282

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: embolization
Description: upper rectal artery embolization with coils

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgical repair
Description: surgical repair through the classic technique (Milligan and Morgan technique)
Study: NCT01674192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prucalopride
Description: single dose of 2 mg prucalopride
Study: NCT03470311

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Benralizumab
Description: 30mg in 1mL pre-filled syringe

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo (1mL) in pre-filled syringe
Study: NCT03091426

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan 1%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan 1.75%

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omiganan
Description: Omiganan 2.5%
Study: NCT02760992

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Baclofen
Description: Baclofen intravenous solution 2 mg/mL manufactured and provided by Allaysis, LLC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Baclofen
Description: 10 mg tablet
Study: NCT03407235

Intervention type: DEVICE
Group type: OTHER
Intervention: Computerized Laparoscopic Trainer
Description: Gold standard laparoscopic trainer using simulated computerized equipment.

Intervention type: DEVICE
Group type: OTHER
Intervention: Box trainer with eye patch
Description: Simple, cost effective box trainer, with loss of dept perception achieved with use of eye patch
Study: NCT01706237

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nexisvision shield
Description: A shield is placed on the eye after LASIK. The shield is similar to a contact lens.
Study: NCT02858492

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772 60 mg
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets thrice daily as directed.
Study: NCT01789827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Radionuclide Imaging
Description: Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Description: Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Technetium Tc 99 Hydrazinonicotinamide-Tricine-linked Interleukin-2
Description: Undergo technetium Tc 99 hydrazinonicotinamide-tricine-linked interleukin-2 scintigraphies